Amplify Weight Loss Drug ...

NYSEArca: THNR · Prix en temps réel · USD
27.73
+0.19 (0.69%)
À la clôture : Aug 27, 2026, 3:59 PM

Amplify Weight Loss Drug & Treatment ETF (THNR) : cours, positions et analyse de l'ETF

0.69%
Bid27.5
Capitalisation boursièren/a
AUM5.07M
NAV27.82
Bêtan / A
EPS (ttm)n / A
Rapport PE (ttm)20.08
Parts en circulationn / A
Date de créationMay 20, 2024
Ask0
Volume9,624
Moy. Volume (20D)2,193
Ouverture27.80
Clôture précédente27.54
Fourchette du jour27.41 - 27.55
Intervalle de 52 semaines22.63 - 27.80
Positionsn / A
Ratio de frais0.59%

À propos de THNR

The fund's manager invests at least 80% of its net assets (plus borrowings for investment purposes) in securities that comprise the index. The index is comprised of global companies expected to economically benefit from weight loss drug development. The index includes pharmaceutical manufacturers, manufacturers of combination therapies and telehealth providers who provide access to Amylin agonists and analogs or GLP-1 agonists and analogs, including dual GLP-1 agonists and analogs. The fund is non-diversified.

Classe d’actifs Equity
Symbole boursier THNR
Date de création May 20, 2024
Fournisseur Amplify Etfs
Échange NYSEArca

Principaux secteurs

SecteurPoids %
Healthcare100.00%
Voir tous les secteurs

10 principaux titres 61.60% des actifs

NomSymbolePoids
Novo Nordisk As AdrNVO9.70%
Eli Lilly And CoLLY8.92%
Regeneron Pharmaceut...REGN6.03%
Cspc Pharmaceutical ...1093.HK5.52%
Arrowhead Pharmaceut...ARWR5.34%
Innovent Biologics I...1801.HK5.34%
Amgen IncAMGN5.25%
Abbvie IncABBV5.24%
Roche Holding Ag Ord...ROP.SW5.20%
Merck & Co IncMRK5.06%
Voir plus de titres

Dividendes Rendement du dividende 1.49%

Ex-dividendeMontantDate de paiement
Dec 30, 2025$0.4130n / A
Dec 30, 2024$0.2200n / A
Historique complet des dividendes